Personalized medicine is one of the main directions in current cancer care. Patients can be pre-screened for different treatments based on genetic profiling and the treatments can be adjusted to each patient accordingly. In photoimmunotherapy the treatment monitoring can be done optically in real-time and adjusting the treatment based on the retrieved data for each patient. To answer this need, Modulight has implemented a minimally invasive real-time optical treatment monitoring unit into medical laser platform ML7710. It has been designed to illuminate and retrieve spectral data from the tumor tissue simultaneously from up to eight different locations. The device can be tailored for several different multi-wavelength illumination and measurement configurations. The automatic drug detection feature in the ML7710 platform is designed to enhance clinicians' decision-making capabilities. By intelligently prioritizing measurement locations based on the presence of fluorescence, this feature serves to minimize unnecessary measurements, consequently reducing both treatment duration and associated risks. In addition to its hardware capabilities, the platform is integrated with a cloud-connected analytics server, which ensures the immediate transfer and real-time processing of all diagnostic and treatment data. This data-driven approach allows for quick adjustments to treatment protocols and sets the stage for improved patient outcomes, contributing to more effective, personalized therapeutic strategies.
|